Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19
OwnerJonathan Alexander TERRETT, Demetrios KALAITZIDIS +2inventors
InventorsJonathan Alexander TERRETT, Demetrios KALAITZIDIS, Ewelina MORAWA, Mark BENTON
Life of this patent
Estimating the term…
Abstract
Methods for treating a B cell malignancy comprising a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and optionally an NK cell inhibitor (e.g., daratumumab). The genetically engineered immune cells may comprise a disrupted TRAC gene, a disrupted β2M gene, or both.
Claims128
A method for treating a B-cell malignancy in a human patient, the method comprising:
- (i) administering to a human patient having a first dose of B-cell malignancy a natural killer (NK) cell inhibitor;
- and
- (ii) administering to the human patient a first dose of a population of genetically engineered T cells after step (ii), wherein the population of genetically engineered T cells comprising T cells that comprise (a) a nucleic acid coding for a chimeric antigen receptor (CAR) that binds CD19;
- optionally wherein the genetically engineered T cells are deficient in expression of MHC Class-I.
A method for treating acute lymphoblastic leukemia (ALL) in a human patient, the method comprising:
- (i) subjecting a human patient having ALL to a lymphodepletion treatment;
- and
- (ii) administering to the human patient a first dose of a population of genetically engineered T cells after step (i),
- wherein the population of genetically engineered T cells comprising T cells comprise (a) a nucleic acid coding for a chimeric antigen receptor (CAR) that binds CD19;
- and
- wherein the first dose of the population of genetically engineered T cells is administered to the human patient at a dose of about 1×107 to about 1×109 CAR+ T cells.
Dependencies are inferred from the claim text.